Aptevo Therapeutics Inc
Most Recent
How Is Bioverativ’s Alprolix Positioned Now?
In 3Q17, Bioverativ’s (BIVV) drug Alprolix generated revenue of $88.5 million, which reflected a rise of ~4% on a year-over-year (or YoY) basis.